G
082270
vs
K
KOSPI 200
Over the past 12 months, GemVax & KAEL Co Ltd has underperformed KOSPI 200, delivering a return of -73% compared to KOSPI 200's +152% growth.
Stocks Performance
082270 vs KOSPI 200
Performance Gap
082270 vs KOSPI 200
Performance By Year
082270 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GemVax & KAEL Co Ltd
Glance View
GemVax & KAEL is a South Korean biopharmaceutical company that develops experimental medicines, with a focus on peptide-based drugs such as GV1001. Its work centers on treatments for diseases with limited options, including cancer and neurodegenerative conditions, and it also has roots in making plasma-derived and other specialty pharmaceutical products. The company makes money in a few ways: by selling pharmaceutical products, by licensing drug technology, and by working with partners on development programs. For investors, the key point is that this is not a broad drugmaker with a large stable of approved medicines; it is more of a research-driven biotech that depends on advancing its own candidates and turning them into licensed or commercial products. Its business model is different from a typical generic manufacturer because much of its value comes from proprietary science and intellectual property rather than high-volume drug production. That means the company’s success depends heavily on clinical progress, regulatory approvals, and partnerships that can turn its research into marketable therapies.
